Structural Heart Devices Market Size was valued at USD 0.71 Billion in 2023. The Global Structural Heart Devices industry is projected to grow from USD 0.77 Billion in 2024 to USD 1.38 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.6% during the forecast period (2024 - 2032).Structural heart disorders and the demand for minimally invasive techniques are the key drivers enhancing market growth.
The Journal of the American College of Cardiology published a study in May 2023 stating that the minimally invasive TAVR technique gave better results compared to open heart surgery throughout three years. The main objective of conducting this study was to examine the long-term effects of TAVR on aortic stenosis patients who participated in the Evolut Low-Risk trial.
For example, in March 2023, Abbott unveiled U.S. FDA approval for its Epic Max tissue valve with stents used for treatment purposes on patients suffering from such conditions as stenosis and aortic regurgitation. This product is the latest addition to the Epic surgical valves platform by Abbott that has shown good clinical outcomes and reliability over time. In addition, it claims to have improved valve hemodynamics.
For instance, in December 2022, Abbott launched Navitor in India. It is an enhanced technology for trans aortic valve implantation (TAVI), which can be applied for severe symptomatic aortic stenosis patients who are considered high or extreme-risk candidates for conventional open-heart surgery. The novelty device obstructs perivalvular leakage, thereby improving transcatheter aortic valve replacement techniques.
In another development, Edwards Lifesciences announced FDA clearance for the SAPIEN 3 Ultra RESILIA TAVR valve, leading advanced stage SAPIEN family testifying the same trend. It brings together RESILIA tissue technology from Edwards Lifesciences with the SAPIEN 3 Ultra TAVR system of devices. They designed new material to reduce re-intervention rates associated with TAVR procedures and expect it will serve as an important part of their next-generation valves at Edwards.
Biometrics, one of America’s leading medical devices contract manufacturers, recently expanded its operations to Ireland after opening Balloons & Balloon Catheters Centre Excellence located on Galway City's western side.
For instance, in May 2022, Centerline Biomedical, Inc. concluded the second in a series of animal studies on structural heart navigation. The possibility of using augmented reality image-guided navigation technology from this company to guide structures of beating hearts was investigated by physicians from Cleveland Clinic’s Heart, Vascular and Thoracic Institute.
In May 2022 Centerline Biomedical, Inc., concluded second of a series of structural heart navigation animal studies. Physicians from Cleveland Clinic's Heart, Vascular and Thoracic Institute evaluated feasibility of utilizing augmented reality image guidance technology by CenterLine Biomedical for navigating structures within live beating heart model. This should contribute towards further product development witnessed over forecast period.
Philips launched EchoNavigator 4.0, the latest version of its image-guided therapy solution for structural heart disease treatment, in May 2022. EchoNavigator 4.0 grants physicians using Philips' EPIQ CVXi interventional cardiology ultrasound system with control of live fusion-imaging on the Azurion - platform, the company's Image Guided Therapy System.
Genesis MedTech Group (Genesis or Group) finalized the acquisition of JC Medical (JCM) in February 2022, a structural heart firm that has mainly engaged in developing and designing transcatheter valve replacement products meant for minimally invasive therapy of structural heart diseases. J-Valve is China's first and only minimally invasive TAVR device approved for aortic regurgitation and stenosis patients it was developed by JCM.
According to BHF UK Factsheet January 2022, approximately 7.6 million individuals live with heart and circulatory diseases in the United Kingdom. Also, as cited before, nearly four million males and 3.6 million females were diagnosed with cardiovascular and heart problems in the country during the year 2021.
In August 2021, the MANTRA (Mitral, Aortic and Tricuspid post-market Study in a real-world setting) trial enrolled its first patient with CORCYM. The first patient was an Italian citizen implanted with a Bicarbon aortic mechanical valve at Citta di Lecce Hospital. This will help drive market growth in future years.
According to this news article from September 2021, Abbott got the FDA's permission for Epic Plus and Epic Plus Supra Stented Tissue Valves that will provide better options for patients living with mitral or aortic valve illness. With this novel device the company expanded its Epic surgical valve platform.
Moreover, Chennai developed First 'Made in India' 3-D printed heart valve in August 2021. These new valves are made through three-dimensional printers to overcome difficulties encountered when using artificial hearts valves. This is likely to lead to greater product development over the future period.
Heart devices include heart valve balloon occludes and annuloplasty rings. If the heart is oversized or has a leaky valve, these devices restructure and tighten the buzz around the heart. Owing to the increasing number of cardiovascular diseases ly, the demand for heart valve devices is growing, further expected to fuel market growth. The article published in June 2022 stated that heart valve surgery is a procedure to treat heart valve disease involving at least one of the four faulty heart valves. Heart valves keep blood flowing in the correct direction through the heart. Thus, the advantages of the devices are anticipated to fuel the Segment's growth.
Additionally, product approvals and new drug launches are the primary factors affecting the availability of a vast concentration of drugs in the market. This is expected to drive segment growth. For instance, in September 2021, Abbott received the Food and Drug Administration (FDA) approval for the company's Epic Plus and Epic Plus Supra Stented Tissue Valves to improve therapy options for people with aortic or mitral valve disease. With this new device, Abbott expanded its Epic surgical valve platform.
In addition, in August 2021, the First 'Made in India' 3-D printed heart valve was developed in Chennai. The new heart valves are designed using 3D printers, which can overcome the problems related to artificial heart valves. Thus, increasing developments are anticipated to drive segment growth over the forecast period. Therefore, a medical condition associated with cardiovascular diseases has recently enhanced the market CAGR of Structural Heart Devices across the globe.
However, there have been significant advances in treatment innovations to cater to the demand. The rising prevalence of cardiovascular diseases (CVDs) ly is another factor driving the growth of the Structural Heart Devices market revenue.
The market segments of Structural Heart Devices, based on type, the segment is divided into Heart Valve Devices, Annuloplasty Rings, Occluders, Delivery Systems. Heart Valve Devices Sweeteners segment held the majority share in 2022concerning the Low-Intensity sweeteners market revenue. Due to its established reimbursement codes and therapeutic efficacy.
LAAC is predicted to be among the segments with the quickest growth in the upcoming years.The procedure's minimally invasive nature is crucial for developing the Structural Heart Devices market revenue.
May 2022Abbott and laboratories announced a distinctive minimally invasive vascular heart valve repair device. The company also revealed new data on two critical components of its market-leading structural heart portfolio, MitraClip, and Amplatzer Amulet.
In May 2022 Biometrics announced its expansion in Ireland with potential in Galway under the Balloons & Balloon Catheters Centre of Excellence.
The market segmentation of Structural Heart Devices has been segmented according to indication into valvular heart disease, cardiomyopathy, congenital heart abnormalities, and others. The two subtypes of valvular heart disease are regurgitation and stenosis. Hence, rising applications of the Segment for biological and tissue valves held a significant market share for structural cardiac devices worldwide. Over the anticipated period, the Segment is likely to dominate the market growth.
Figure 1 Structural Heart Devices Market, by Indication, 2023 & 2032 (USD Billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
The Structural Heart Devices market data has been divided into six categories based on procedure is divided into two categories based on technique replacement process and repair procedure. Throughout the projected period, the replacement procedure segment is expected to account for a sizeable portion of the market due to the availability of cutting-edge technology, & cost-effective treatments.
In May 2022Philips launched EchoNavigator 4.0, the new release of its image-guided therapy solution for treating structural heart disease. EchoNavigator 4.0 gives users of Philips’ EPIQ CVXi interventional cardiology ultrasound system a control of live fusion-imaging on the company’s Image Guided Therapy System called “Azurion – platform.”
In February 2022Genesis MedTech Group (Genesis or Group) completed the acquisition of JC Medical (JCM). This structural heart company primarily designs and develops transcatheter valve replacement products for the minimally invasive treatment of structural heart diseases. J-Valve, developed by JCM, is the first and only in China to successfully develop and commercialize a minimally invasive TAVR device approved for both aortic regurgitation and stenosis patients.
By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Structural Heart device market accounted for USD 4.5 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. This is attributed to the rate of endovascular procedures has increased as well as invasive procedures across the Region.
Further, the significant countries studied in the market report are The U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3 STRUCTURAL HEART DEVICES MARKET SHARE BY REGION 2023 (%)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe's Structural Heart Devices market accounts for the second-largest market share due to indications into valvular heart disease, cardiomyopathy, congenital heart abnormalities, and others. The two subtypes of valvular heart disease are regurgitation and stenosis. Hence, rising applications of the Segment for biological and tissue valves held a significant market share for structural cardiac devices worldwide. Further, the Germany market of Structural Heart Devices had the largest market share, and the UK market of Structural Heart Devices was the fastest-growing market in the European Region.
The Asia-Pacific Structural Heart Devices Market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to increased rates of cardiovascular disease in the rapidly evolving healthcare industry. Moreover, Japan's market of Structural Heart Devices held the largest market share, and the India market of Structural Heart Devices was the fastest-growing market in the Asia-Pacific region.
Structural Heart Devices Key Market Players& Competitive Insights
Major market players are spending a lot on R&D to increase their product lines, which will help the market of Structural Heart Devices grow even more. Market participants are also taking various strategic initiatives to develop their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Structural Heart Devices industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies manufacturers adopt in the Structural Heart Devices industry to benefit clients and expand the market sector is manufacturing locally to reduce operating costs. The structural Heart devices industry has provided medicine with some of the most significant benefits in recent years. The Structural Heart Devices market major player such as Edwards Lifesciences Corporation (US), Medtronic plc (Ireland), Abbott (US), Boston Scientific Corporation (US), LivaNova plc (UK), ST. Jude Medical, Biomerics, ComedBV,JenaValve Technology Inc.,CardioKinetix,Cook Group Incorporated (US), and others are working on expanding the market demand by investing in research and development activities.
Philips, is a Dutch multinational conglomerate corporation that was founded in Eindhoven in 1891. Since 1997, it has been mostly headquartered in Amsterdam, though the Benelux headquarters is still in Eindhoven. Philips launched EchoNavigator 4.0, the new release of its image-guided therapy solution for treating structural heart disease. EchoNavigator 4.0 gives users of Philips’ EPIQ CVXi interventional cardiology ultrasound system a control of live fusion-imaging on the company’s Image Guided Therapy System called “Azurion – platform.”
Genesis MedTech Group is a medical device company headquartered in Singapore. Founded by professionals and entrepreneurs with MedTech experience ly and in Asia, its product portfolio focuses on value segment multi-therapy medical device products for emerging markets with sales and distribution through its established commercial network. Genesis MedTech Group covers the entire industry value chain of research and development, manufacturing, quality management, supply chain, marketing, and sales. Genesis MedTech Group (Genesis or Group) completed the acquisition of JC Medical (JCM). This structural heart company primarily designs and develops transcatheter valve replacement products for the minimally invasive treatment of structural heart diseases. J-Valve, developed by JCM, is the first and only in China to successfully develop and commercialize a minimally invasive TAVR device approved for both aortic regurgitation and stenosis patients.
Key Companies in the market of Structural Heart Devices include
Structural Heart Devices Industry Developments
In May 2022 Philips launched EchoNavigator 4.0, the new release of its image-guided therapy solution for treating structural heart disease. EchoNavigator 4.0 gives users of Philips’ EPIQ CVXi interventional cardiology ultrasound system a control of live fusion-imaging on the company’s Image Guided Therapy System called “Azurion – platform.”
In February 2022 GenesisMedTech Group (Genesis or Group) completed the acquisition of JC Medical (JCM). This structural heart company primarily designs and develops transcatheter valve replacement products for the minimally invasive treatment of structural heart diseases. J-Valve, developed by JCM, is the first and only in China to successfully develop and commercialize a minimally invasive TAVR device approved for both aortic regurgitation and stenosis patients.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.71 billion |
| Market Size 2024 | USD 0.77 billion |
| Market Size 2032 | USD 1.38 billion |
| Compound Annual Growth Rate (CAGR) | 6.6% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2019- 2021 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Indication, Procedure, and Region |
| Geographies Covered | North America, Europe, AsiaPacific, and the Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Edwards Lifesciences Corporation (US), Medtronic plc (Ireland), Abbott (US), Boston Scientific Corporation (US), LivaNova plc (UK), ST. Jude Medical, Biomerics, ComedBV,JenaValve Technology Inc.,CardioKinetix,Cook Group Incorporated (US) |
| Key Market Opportunities | Rise in emphasis of key players on research and development activities of structural heart devices. Increase in demand for rapid and long-lasting procedures |
| Key Market Dynamics | The rise in the frequency of structural heart diseases Rise in demand for minimally invasive techniques |
Structural Heart Devices Market Highlights:
Frequently Asked Questions (FAQ) :
The Structural Heart Devices market size was valued at USD 0.71 Billion in 2023.
The market is projected to grow at a CAGR of 6.6% during the forecast period, 2024-2032.
North America had the largest share of the market
The key players in the market are Edwards Lifesciences Corporation (US), Medtronic plc (Ireland), Abbott (US), Boston Scientific Corporation (US), LivaNova plc (UK), and ST. Jude Medical, Biomerics, ComedBV,JenaValve Technology Inc.,CardioKinetix,Cook Group Incorporated (US)
The Valve devices Heart Devicescategory dominated the market in 2022.
Asia Pacific is growing at the highest CAGR over 2024 – 2032.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
